These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28105731)

  • 1. Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
    von Scholten BJ; Persson F; Rosenlund S; Eugen-Olsen J; Pielak T; Faber J; Hansen TW; Rossing P
    Diabetes Obes Metab; 2017 Jun; 19(6):901-905. PubMed ID: 28105731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study.
    Sujana C; Seissler J; Jordan J; Rathmann W; Koenig W; Roden M; Mansmann U; Herder C; Peters A; Thorand B; Then C
    Cardiovasc Diabetol; 2020 Oct; 19(1):178. PubMed ID: 33066780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of liraglutide on renal function: A randomized clinical trial.
    von Scholten BJ; Persson F; Rosenlund S; Hovind P; Faber J; Hansen TW; Rossing P
    Diabetes Obes Metab; 2017 Feb; 19(2):239-247. PubMed ID: 27753201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.
    Pavo N; Raderer M; Hülsmann M; Neuhold S; Adlbrecht C; Strunk G; Goliasch G; Gisslinger H; Steger GG; Hejna M; Köstler W; Zöchbauer-Müller S; Marosi C; Kornek G; Auerbach L; Schneider S; Parschalk B; Scheithauer W; Pirker R; Drach J; Zielinski C; Pacher R
    Heart; 2015 Dec; 101(23):1874-80. PubMed ID: 26416836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes.
    Nielsen R; Jorsal A; Tougaard RS; Rasmussen JJ; Schou M; Videbaek L; Gustafsson I; Faber J; Flyvbjerg A; Wiggers H; Tarnow L; Kistorp C
    Diabetes Obes Metab; 2020 Nov; 22(11):2141-2150. PubMed ID: 32627271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midregional fragment of proadrenomedullin, new-onset albuminuria, and cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-30).
    Landman GW; van Dijk PR; Drion I; van Hateren KJ; Struck J; Groenier KH; Gans RO; Bilo HJ; Bakker SJ; Kleefstra N
    Diabetes Care; 2014; 37(3):839-45. PubMed ID: 24170764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
    Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
    J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS.
    Frøssing S; Nylander M; Kistorp C; Skouby SO; Faber J
    Endocr Connect; 2018 Jan; 7(1):115-123. PubMed ID: 29295870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-Term Influence of Radiofrequency Ablation on NT-proBNP, MR-proANP, Copeptin, and MR-proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study.
    Charitakis E; Walfridsson H; Alehagen U
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple endothelial biomarkers and noninvasive vascular function in the general population: the Gutenberg Health Study.
    Schnabel RB; Wild PS; Schulz A; Zeller T; Sinning CR; Wilde S; Kunde J; Lubos E; Lackner KJ; Warnholtz A; Gori T; Blankenberg S; Munzel T;
    Hypertension; 2012 Aug; 60(2):288-95. PubMed ID: 22689741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular biomarkers in preeclampsia at triage.
    Wellmann S; Benzing J; Fleischlin S; Morgenthaler N; Fouzas S; Bührer CA; Szinnai G; Burkhardt T; Lapaire O
    Fetal Diagn Ther; 2014; 36(3):202-7. PubMed ID: 24853905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.
    von Scholten BJ; Lajer M; Goetze JP; Persson F; Rossing P
    Diabet Med; 2015 Mar; 32(3):343-52. PubMed ID: 25251901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide and Renal Outcomes in Type 2 Diabetes.
    Mann JFE; Ørsted DD; Brown-Frandsen K; Marso SP; Poulter NR; Rasmussen S; Tornøe K; Zinman B; Buse JB;
    N Engl J Med; 2017 Aug; 377(9):839-848. PubMed ID: 28854085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial.
    Joergensen C; Tarnow L; Goetze JP; Rossing P
    Diabet Med; 2015 Mar; 32(3):374-81. PubMed ID: 25307511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copeptin, B-type natriuretic peptide and cystatin C are associated with incident symptomatic PAD.
    Fatemi S; Acosta S; Gottsäter A; Melander O; Engström G; Dakhel A; Zarrouk M
    Biomarkers; 2019 Sep; 24(6):615-621. PubMed ID: 31215249
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Margulies KB; Hernandez AF; Redfield MM; Givertz MM; Oliveira GH; Cole R; Mann DL; Whellan DJ; Kiernan MS; Felker GM; McNulty SE; Anstrom KJ; Shah MR; Braunwald E; Cappola TP;
    JAMA; 2016 Aug; 316(5):500-8. PubMed ID: 27483064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mid-regional pro-adrenomedullin (MR-proADM) and mid-regional pro-atrial natriuretic peptide (MR-proANP) in severe aortic valve stenosis: association with outcome after transcatheter aortic valve implantation (TAVI).
    Baldenhofer G; Laule M; Mockel M; Sanad W; Knebel F; Dreger H; Leonhardt F; Sander M; Grubitzsch H; Baumann G; Stangl K; Stangl V
    Clin Chem Lab Med; 2017 Feb; 55(2):275-283. PubMed ID: 27522619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.
    Kolditz M; Seyfarth HJ; Wilkens H; Ewert R; Bollmann T; Dinter C; Hertel S; Klose H; Opitz C; Grünig E; Höffken G; Halank M
    Lung; 2015 Dec; 193(6):901-10. PubMed ID: 26363916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.